Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, 2-Period Crossover Trial to Determine the Relative Bioavailability of CE-Iohexol (Iohexol/Sulfobutylether-β-Cyclodextrin (Captisol) Injection and Omnipaque (Iohexol) Injection in Healthy Adult Volunteers

Trial Profile

A Randomized, Double-Blind, 2-Period Crossover Trial to Determine the Relative Bioavailability of CE-Iohexol (Iohexol/Sulfobutylether-β-Cyclodextrin (Captisol) Injection and Omnipaque (Iohexol) Injection in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iohexol (Primary)
  • Indications Cardiovascular disorders
  • Focus Pharmacokinetics; Registrational
  • Sponsors CyDex Pharmaceuticals

Most Recent Events

  • 08 Nov 2019 According to a Ligand Pharmaceuticals media release, data from this trial was presented at the ASN Kidney Week 2019.
  • 08 Nov 2019 Results published in the Ligand Pharmaceuticals media release
  • 05 Nov 2019 According to a Ligand Pharmaceuticals media release, data from this trial will be presented at ASN Kidney Week 2019 in Washington, DC on November 8th, 2019 and the 2019 Contrast Media Research Symposium in Erice, Italy on November 11th, 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top